share_log

Morphic (NASDAQ:MORF) Shares Gap Up to $27.69

Morphic (NASDAQ:MORF) Shares Gap Up to $27.69

莫尼克(納斯達克：MORF)股價差距高達27.69美元
Financial News Live ·  2022/09/07 11:41

Morphic Holding, Inc. (NASDAQ:MORF – Get Rating) shares gapped up before the market opened on Wednesday . The stock had previously closed at $27.69, but opened at $28.42. Morphic shares last traded at $27.91, with a volume of 128 shares.

Moric Holding，Inc.(納斯達克代碼：Morf-Get Rating)股價在週三開盤前大幅上漲。該股此前收盤報27.69美元，開盤報28.42美元。Moric股票最新報27.91美元，成交量為128股。

Analyst Ratings Changes

分析師評級發生變化

Several research firms recently commented on MORF. BMO Capital Markets reiterated a "buy" rating and issued a $83.00 price objective on shares of Morphic in a research report on Friday, August 5th. Stifel Nicolaus assumed coverage on Morphic in a research report on Tuesday. They set a "buy" rating and a $44.00 price target for the company. Wells Fargo & Company reduced their price objective on Morphic from $79.00 to $77.00 and set an "overweight" rating on the stock in a research report on Thursday, August 4th. SVB Leerink initiated coverage on Morphic in a research report on Wednesday, July 20th. They set an "outperform" rating and a $45.00 price objective for the company. Finally, Royal Bank of Canada decreased their price target on shares of Morphic from $76.00 to $70.00 and set an "outperform" rating on the stock in a research note on Thursday, August 4th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $64.43.

幾家研究公司最近對Morf發表了評論。蒙特利爾銀行資本市場在8月5日星期五的一份研究報告中重申了買入評級，併發布了Morphi股票83.00美元的目標價。Stifel Nicolaus在週二的一份研究報告中對Morphi進行了報道。他們為該公司設定了“買入”評級和44.00美元的目標價。富國銀行在8月4日(星期四)的一份研究報告中將Morphi的目標價從79.00美元下調至77.00美元，並對該股設定了“增持”評級。SVB Leerink在7月20日(星期三)的一份研究報告中啟動了Morphi的報道。他們為該公司設定了“跑贏大盤”的評級和45.00美元的目標價。最後，加拿大皇家銀行在8月4日(星期四)的一份研究報告中將Morphi的目標價從76.00美元下調至70.00美元，並對該股設定了“跑贏大盤”的評級。根據MarketBeat.com的數據，八位投資分析師對該股的評級為買入，目前該股的共識評級為買入，共識目標價為64.43美元。

Get
到達
Morphic
形態
alerts:
警報：

Morphic Price Performance

形態性價比

The stock has a 50-day simple moving average of $26.94 and a 200-day simple moving average of $30.89. The stock has a market cap of $1.10 billion, a PE ratio of -19.66 and a beta of 1.46.

該股的50日簡單移動均線切入位為26.94美元，200日簡單移動均線切入位為30.89美元。該股市值為11.億美元，市盈率為-19.66，貝塔係數為1.46。

Institutional Inflows and Outflows

機構資金流入和流出

Hedge funds have recently bought and sold shares of the business. Virtus ETF Advisers LLC raised its stake in shares of Morphic by 12.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 3,693 shares of the company's stock valued at $175,000 after acquiring an additional 420 shares during the period. Rhumbline Advisers raised its stake in shares of Morphic by 2.4% during the fourth quarter. Rhumbline Advisers now owns 20,800 shares of the company's stock valued at $986,000 after purchasing an additional 480 shares during the period. Point72 Hong Kong Ltd lifted its holdings in Morphic by 983.3% in the 4th quarter. Point72 Hong Kong Ltd now owns 715 shares of the company's stock worth $34,000 after buying an additional 649 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Morphic by 1.5% in the first quarter. Bank of New York Mellon Corp now owns 69,380 shares of the company's stock worth $2,786,000 after acquiring an additional 1,004 shares in the last quarter. Finally, Silverarc Capital Management LLC boosted its holdings in Morphic by 1.9% in the first quarter. Silverarc Capital Management LLC now owns 68,709 shares of the company's stock valued at $2,759,000 after purchasing an additional 1,269 shares during the last quarter. Hedge funds and other institutional investors own 81.64% of the company's stock.
對衝基金最近買賣了該公司的股票。Virtus ETF Advisers LLC在第四季度將其在Morphy的持股比例提高了12.8%。Virtus ETF Advisers LLC在此期間額外購買了420股，現在擁有3693股該公司的股票，價值17.5萬美元。Rhumbline Advisers在第四季度將其在Morphi的持股比例提高了2.4%。在此期間，Rhumbline Advisers又購買了480股，現在擁有20,800股該公司股票，價值98.6,000美元。Point72 Hong Kong Ltd在第四季度增持了Morphi 983.3%的股份。Point72 Hong Kong Ltd現在持有該公司715股股票，價值3.4萬美元，上一季度又購買了649股。今年第一季度，紐約梅隆銀行(Bank Of New York Mellon Corp)增持了Morphi股票1.5%。紐約梅隆銀行(Bank Of New York Mellon Corp)目前持有69,380股該公司股票，價值2,786,000美元，此前該公司在上一季度額外收購了1,004股。最後，SilverarcCapital Management LLC在第一季度將其在Morphy的持股增加了1.9%。SilverarcCapital Management LLC現在擁有68709股該公司的股票，價值275.9萬美元，在上個季度又購買了1269股。對衝基金和其他機構投資者持有該公司81.64%的股票。

Morphic Company Profile

形態化的公司簡介

(Get Rating)

(獲取評級)

Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases.

生物製藥公司Moric Holding，Inc.發現和開發用於治療自身免疫、心血管、代謝性疾病以及纖維化和癌症的口服小分子整合素療法。它的主要候選產品是Morf-057，這是一種A4？7特定的影響炎症的整合素抑制劑，目前處於治療炎症性腸病的第一階段臨牀試驗；以及治療特發性肺纖維化和纖維化疾病的臨牀前試驗。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on Morphic (MORF)
  • REV Group Has A Deep Moat In The World Of EVs
  • Is G-III Apparel Group, Ltd. A Value Trap?
  • Bank Of America Sees Upside In These 2 European Alcohol Stocks
  • 3 Low Beta Defensive Stocks for a Tough Market
  • It Could Be a September to Remember for These 3 Stocks
  • 免費獲取StockNews.com關於Morphy的研究報告(Morf)
  • REV集團在電動汽車世界擁有深厚的護城河
  • G-III服裝集團有限公司是價值陷阱嗎？
  • 美國銀行看好這兩隻歐洲酒類股票
  • 3低貝塔防禦性股票為艱難的市場做準備
  • 對於這三隻股票來説，這可能是一個值得記住的9月

Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.

接受Morphy Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對Morphi及相關公司評級的每日簡明摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論